A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

Journal of Experimental Medicine

Volumn 205, Issue 8, 2008, Pages 1869-1877

  Björkqvist, Maria ^a   Wild, Edward J ^b   Thiele, Jenny ^c   Silvestroni, Aurelio ^d   Andre, Ralph ^b   Lahiri, Nayana ^b   Raibon, Elsa ^d   Lee, Richard V ^d   Benn, Caroline L ^e   Soulet, Denis ^a   Magnusson, Anna ^a   Woodman, Ben ^e   Landles, Christian ^e   Pouladi, Mahmoud A ^c   Hayden, Michael R ^e   Khalili Shirazi, Azadeh ^b   Lowdell, Mark W ^f   Brundin, Patrik ^a   Bates, Gillian P ^e   Leavitt, Blair R ^c   Möller, Thomas ^d   Tabrizi, Sarah J ^b   more..

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e GUY S HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL STIMULATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; FEMALE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INNATE IMMUNITY; KNOWLEDGE; MACROPHAGE; MALE; MICROGLIA; MONOCYTE; MOUSE; MUTANT; NONHUMAN; PATHOGENESIS; PATHOLOGY; PLASMA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYMPTOM;

ANIMALS; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM; CYTOKINES; GENE EXPRESSION; HUMANS; HUNTINGTON DISEASE; MACROPHAGES; MICE; MICE, TRANSGENIC; MICROGLIA; MODELS, IMMUNOLOGICAL; MONOCYTES; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 49249089029     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20080178     Document Type: Article

References (36)

1. Bates, G., P.S. Harper, and L. Jones, editors. 2002. Huntington's Disease. Oxford University Press, Oxford. 558 pp.
2. Sathasivam, K., C. Hobbs, M. Turmaine, L. Mangiarini, A. Mahal, F. Bertaux, E.E. Wanker, P. Doherty, S.W. Davies, and G.P. Bates. 1999. Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 8:813-822.
3. Van Raamsdonk, J.M., Z. Murphy, D.M. Selva, R. Hamidizadeh, J. Pearson, A. Petersen, M. Bjorkqvist, C. Muir, I.R. Mackenzie, G.L. Hammond, et al. 2007. Testicular degeneration in Huntington disease. Neurobiol. Dis. 26:512-520.
4. Robbins, A.O., A.K. Ho, and R.A. Barker. 2006. Weight changes in Huntington's disease. Eur. J. Neurol. 13:e7.
5. Bjorkqvist, M., A. Petersen, K. Bacos, J. Isaacs, P. Norlen, J. Gil, N. Popovic, F. Sundler, G.P. Bates, S.J. Tabrizi, et al. 2006. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 15:1713-1721.
6. Dalrymple, A., E.J. Wild, R. Joubert, K. Sathasivam, M. Bjorkqvist, A. Petersen, G.S. Jackson, J.D. Isaacs, M. Kristiansen, G.P. Bates, et al. 2007. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6:2833-2840.
7. Khoshnan, A., J. Ko, E.E. Watkin, L.A. Paige, P.H. Reinhart, and P.H. Patterson. 2004. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 24:7999-8008.
8. Gasque, P., M. Fontaine, and B.P. Morgan. 1995. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154:4726-4733.
9. Hodges, A., A.D. Strand, A.K. Aragaki, A. Kuhn, T. Sengstag, G. Hughes, L.A. Elliston, C. Hartog, D.R. Goldstein, D. Thu, et al. 2006. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15:965-977.
10. Tai, Y.F., N. Pavese, A. Gerhard, S.J. Tabrizi, R.A. Barker, D.J. Brooks, and P. Piccini. 2007. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 130:1759-1766.
11. Sapp, E., K.B. Kegel, N. Aronin, T. Hashikawa, Y. Uchiyama, K. Tohyama, P.G. Bhide, J.P. Vonsattel, and M. DiFiglia. 2001. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60:161-172.
12. Pavese, N., A. Gerhard, Y.F. Tai, A.K. Ho, F. Turkheimer, R.A. Barker, D.J. Brooks, and P. Piccini. 2006. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 66:1638-1643.
13. Shin, J.-Y., Z.-H. Fang, Z.-X. Yu, C.-E. Wang, S.-H. Li, and X.-J. Li. 2005. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171:1001-1012.
14. Langbehn, D.R., R.R. Brinkman, D. Falush, J.S. Paulsen, and M.R. Hayden. 2004. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 65:267-277.
15. Kindt, T.J., R.A. Goldsby, B.A. Osborne, and J. Kuby. 2006. Kuby Immunology. W.H. Freeman, New York. 608 pp.
16. The Huntington Study Group. 1996. Unified Huntington's disease rating scale: reliability and consistency. Mov. Disord. 11:136-142.
17. Wild, E.J., and S.J. Tabrizi. 2006. Predict-HD and the future of therapeutic trials. Lancet Neurol. 5:724-725.
18. Mangiarini, L., K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S.W. Davies, and G.P. Bates. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:493-506.
19. Woodman, B., R. Butler, C. Landles, M.K. Lupton, J. Tse, E. Hockly, H. Moffitt, K. Sathasivam, and G.P. Bates. 2007. The HdhQ150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 72:83-97.
20. Bozic, C.R., L.F. Kolakowski Jr., N.P. Gerard, C. Garcia-Rodriguez, C. von Uexkull-Guldenband, M.J. Conklyn, R. Breslow, H.J. Showell, and C. Gerard. 1995. Expression and biologic characterization of the murine chemokine KC. J. Immunol. 154:6048-6057.
21. Slow, E.J., J. van Raamsdonk, D. Rogers, S.H. Coleman, R.K. Graham, Y. Deng, R. Oh, N. Bissada, S.M. Hossain, Y.Z. Yang, et al. 2003. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12:1555-1567.
22. Fietta, A.M., M. Morosini, F. Meloni, A.M. Bianco, and E. Pozzi. 2002. Pharmacological analysis of signal transduction pathways required for mycobacterium tuberculosis-induced IL-8 and MCP-1 production in human peripheral monocytes. Cytokine. 19:242-249.
23. Steensberg, A., M.K. Dalsgaard, N.H. Secher, and B.K. Pedersen. 2006. Cerebrospinal fluid IL-6, HSP72, and TNF-alpha in exercising humans. Brain Behav. Immun. 20:585-589.
24. Billiau, A.D., P. Witters, B. Ceulemans, A. Kasran, C. Wouters, and L. Lagae. 2007. Intravenous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile. Epilepsia. 48:1739-1749.
25. Hersch, S.M., S. Gevorkian, K. Marder, C. Moskowitz, A. Feigin, M. Cox, P. Como, C. Zimmerman, M. Lin, L. Zhang, et al. 2006. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 66:250-252.
26. Pan, W., and A.J. Kastin. 2007. Adipokines and the blood-brain barrier. Peptides. 28:1317-1330.
27. Lobsiger, C.S., and D.W. Cleveland. 2007. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 10:1355-1360.
28. Giorgini, F., P. Guidetti, Q. Nguyen, S.C. Bennett, and P.J. Muchowski. 2005. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 37:526-531.
29. Ray, S., M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, K. Blennow, L.F. Friedman, D.R. Galasko, M. Jutel, A. Karydas, et al. 2007. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13:1359-1362.
30. Lin, C.H., S. Tallaksen-Greene, W.M. Chien, J.A. Cearley, W.S. Jackson, A.B. Crouse, S. Ren, X.J. Li, R.L. Albin, and P.J. Detloff. 2001. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10:137-144.
31. Gabert, J., E. Beillard, V.H. van der Velden, W. Bi, D. Grimwade, N. Pallisgaard, G. Barbany, G. Cazzaniga, J.M. Cayuela, H. Cave, et al. 2003. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 17:2318-2357.
32. Weydt, P., E.C. Yuen, B.R. Ransom, and T. Moller. 2004. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia. 48:179-182.
33. Pfaffl, M.W. 2001. Validities of mRNA quantification using recombinant RNA and recombinant DNA external calibration curves in realtime RT-PCR. Biotechnol. Lett. 23:275.
34. Savitz, D.A., and A.F. Olshan. 1995. Multiple comparisons and related issues in the interpretation ofepidemiologic data. Am. J. Epidemiol. 142:904-908.
35. Teunissen, C.E., D. Lutjohann, K. von Bergmann, F. Verhey, F. Vreeling, A. Wauters, E. Bosmans, H. Bosma, M.P.J. van Boxtel, M. Maes, et al. 2003. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol. Aging. 24:893-902.
36. Hanley, J.A., and B.J. McNeil. 1982. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143:29-36.